Abstract
CYP2C19 is one of the principal enzymes involved in the metabolism of clopidogrel. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function. A loss-of-function allele, CYP2C19*2, is associated with an increased risk of major adverse cardiovascular events, particularly stent thrombosis, in patients with acute coronary syndromes who are receiving clopidogrel, especially among those undergoing percutaneous coronary intervention. Newer, more potent P2Y12 inhibitors like prasugrel and ticagrelor have been introduced recently in the daily clinical practice with better cardiovascular outcome in these patients. The purpose of this review article is to provide information regarding the clinical use of CYP2C19 genotyping in patients requiring antiplatelet therapy.
Keywords: Clopidogrel, prasugrel, ticagrelor, percutaneous coronary intervention, CYP2C19 polymorphism, enzymes, metabolism, clinical practice, genotyping, cardiovascular events
Current Pharmaceutical Design
Title:Cytochrome P450 2C19 Polymorphism and Antiplatelet Therapy. Who Should Really be Genotyped?
Volume: 19 Issue: 13
Author(s): George Kassimis, Eleana F. Stavrou, Dimitrios Alexopoulos and Aglaia Athanassiadou
Affiliation:
Keywords: Clopidogrel, prasugrel, ticagrelor, percutaneous coronary intervention, CYP2C19 polymorphism, enzymes, metabolism, clinical practice, genotyping, cardiovascular events
Abstract: CYP2C19 is one of the principal enzymes involved in the metabolism of clopidogrel. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function. A loss-of-function allele, CYP2C19*2, is associated with an increased risk of major adverse cardiovascular events, particularly stent thrombosis, in patients with acute coronary syndromes who are receiving clopidogrel, especially among those undergoing percutaneous coronary intervention. Newer, more potent P2Y12 inhibitors like prasugrel and ticagrelor have been introduced recently in the daily clinical practice with better cardiovascular outcome in these patients. The purpose of this review article is to provide information regarding the clinical use of CYP2C19 genotyping in patients requiring antiplatelet therapy.
Export Options
About this article
Cite this article as:
Kassimis George, F. Stavrou Eleana, Alexopoulos Dimitrios and Athanassiadou Aglaia, Cytochrome P450 2C19 Polymorphism and Antiplatelet Therapy. Who Should Really be Genotyped?, Current Pharmaceutical Design 2013; 19 (13) . https://dx.doi.org/10.2174/1381612811319130017
DOI https://dx.doi.org/10.2174/1381612811319130017 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus
Current Signal Transduction Therapy The Biology of the Peroxisome Proliferator-activated Receptor System in the Female Reproductive Tract
Current Pharmaceutical Design Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets From Structure – Based to Knowledge – Based Drug Design Through X-Ray Protein Crystallography: Sketching Glycogen Phosphorylase Binding Sites
Current Medicinal Chemistry Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder
Current Psychiatry Reviews Novel Swellable/Expandable Gastroretentive Floating Films of Gliclazide Folded in Capsule Shell for the Effective Management of Diabetes Mellitus: Formulation Development, Optimization and In Vitro Evaluation
Current Drug Therapy Cholesterol Ester Transfer Protein (CETP), Postprandial Lipemia and Hypolipidemic Drugs
Current Medicinal Chemistry Glaucoma Disease: A Survey
Current Medical Imaging 3D-QSAR Studies on a Series of 2,4-Thiazolidinedione Derivatives: A Self- Organizing Molecular Field Analysis Approach to Design Novel PTP 1B Inhibitors
Medicinal Chemistry Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Special Issue on New Cellular, Genetic and Proteomic Tools in the Prevention and Management of Diabetes Mellitus
Current Medicinal Chemistry Cardiovascular effect of Nigella sativa L. Aqueous Extract in Normal Rats
Cardiovascular & Hematological Disorders-Drug Targets A Hybrid Binary Cuckoo Search and Genetic Algorithm for Feature Selection in Type-2 Diabetes
Current Bioinformatics A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Current Diabetes Reviews Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Oxidative Stress Correlates (OSC) in Diabetes Mellitus Patients
Current Diabetes Reviews